SCHEMBL16619335

SCHEMBL16619335

NCCOCCOCCNC(=O)c1ccc(-c2nc3ccccc3[nH]2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALB P02768 1/20 0.62
HPSE Q9Y251 2/20 0.57
ATR Q13535 3/20 0.55
KDM4E B2RXH2 3/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
ALDH1A1 P00352 2/20 0.55
HPGD P15428 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
LMNA P02545 1/20 0.55
PKM P14618 1/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
MMP2 P08253 2/20 0.54
MMP9 P14780 2/20 0.54
MMP8 P22894 2/20 0.54
MMP13 P45452 2/20 0.54
KMT2A Q03164 3/20 0.52
FLT3 P36888 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16619475 0.88 HDAC6 (0.58) ALBMMP2MMP9MMP8FLT3
SCHEMBL21017842 0.83 ALB (0.51) ALBKDM4ENPC1RAB9AALDH1A1
SCHEMBL21017631 0.83 ALB (0.51) ALBKDM4ENPC1RAB9AALDH1A1
SCHEMBL16630755 0.79 ALB (1.00) ALBHPSEATRKDM4ENPC1
SCHEMBL16619809 0.78 ALB (0.71) ALBATRFLT3
SCHEMBL10064731 0.76 SMN1; SMN2 (0.84) NPC1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL28984149 0.76 SMN1; SMN2 (0.84) NPC1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL5943810 0.75 HPSE (0.75) HPSEKDM4ENPC1RAB9AALDH1A1
SCHEMBL5652034 0.75 FLT3 (0.58) ATRKDM4EFLT3HDAC3HDAC1
SCHEMBL20982580 0.75 HDAC6 (0.62) HDAC3HDAC1HDAC2HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052483-A1 COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT GlaxoSmithKline Intellectual Property Development Limited (GB) 2016-08-10 EP claimed
US-20160221962-A1 COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-08-04 US claimed
WO-2015049651-A1 COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-04-09 WO claimed
EP-3052483-B1 COMPOUNDS FOR AFFINITY CHROMATOGRAPHY GLAXOSMITHKLINE IP DEV LTD (GB) 2019-02-06 EP disclosed
EP-3052483-B1 COMPOUNDS FOR AFFINITY CHROMATOGRAPHY GLAXOSMITHKLINE IP DEV LTD (GB) 2019-02-06 EP disclosed
US-9938243-B2 Compounds for affinity chromatography and for extending the half-life of a therapeutic agent GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-04-10 US disclosed
US-9938243-B2 Compounds for affinity chromatography and for extending the half-life of a therapeutic agent GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-04-10 US disclosed
US-20170369448-A1 COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-28 US disclosed
US-9809558-B2 Compounds for affinity chromatography and for extending the half-life of a therapeutic agent GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-11-07 US disclosed
US-9809558-B2 Compounds for affinity chromatography and for extending the half-life of a therapeutic agent GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-11-07 US disclosed
EP-3052483-A1 COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT GlaxoSmithKline Intellectual Property Development Limited (GB) 2016-08-10 EP disclosed
US-20160221962-A1 COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-08-04 US disclosed
US-20160221962-A1 COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-08-04 US disclosed
WO-2015049651-A1 COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-04-09 WO disclosed
WO-2015049651-A1 COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221962-A1 COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT ALB, HDGF, VEGFA ALB 1/4885HPSE 264/4885ATR 4307/4885
US-20170369448-A1 COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT ALB, HDGF, VEGFA ALB 1/4885HPSE 264/4885ATR 4307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.